Skip to main content
Premium Trial:

Request an Annual Quote

Full Steam Ahead

Writedit at Medical Writing, Editing & Grantsmanship raises concerns about the speed with which the Scientific Management Review Board of the National Institutes of Health decided to create a new translational medicine center. At a meeting last month, both NIH director Francis Collins and Arthur Rubenstein, Translational Medicine and Therapeutics Working Group chair, said that the consequences of creating a new institute would have to be deliberated further, but, as Writedit points out, the very next item on the agenda dealt with how the new center could work with NIH's Clinical Center — indicating that the new institute was essentially a done deal. She goes on to doubt that NIH and the SMRB took a comprehensive look at the options and indicates that discussions over alternatives seem to have been stifled. "If such major changes can be implemented so quickly with such little input beyond 'working' group members, what else might the SMRB do on behalf of NIH directors seeking to push through special initiatives?" she asks.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.